BeOne Medicines AG
NASDAQ: ONC0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- John V. Oyler
- Employees
- 12,000
- Headquarters
- Basel, United States
- IPO year
- 2016
- Market cap
- $31.1B
- Website
- https://beonemedicines.com
Loading ONC…
Loading profile data…Frequently asked questions about ONC
What does BeOne Medicines AG (ONC) do?
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA...
Where does ONC trade?
BeOne Medicines AG (ONC) trades on the NASDAQ.
What sector is ONC in?
BeOne Medicines AG (ONC) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of BeOne Medicines AG?
John V. Oyler is the chief executive officer of BeOne Medicines AG (ONC).
Where is BeOne Medicines AG headquartered?
BeOne Medicines AG is headquartered in United States.
Does ONC pay a dividend?
BeOne Medicines AG (ONC) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ONC go public?
BeOne Medicines AG (ONC) completed its initial public offering in 2016.